Free press releases distribution network?

Agency / Source: Covance, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Covance Announces Biomarker Expert Team Dedicated to Development Validation Testing of Biomarkers - World's largest biomarker testing company forms expert team to expedite biopharmaceutical customer need for high throughput assay services
Covance Announces Biomarker Expert Team Dedicated to Development Validation Testing of Biomarkers

 

PRZOOM - /newswire/ - Princeton, NJ, United States, 2007/04/27 - World's largest biomarker testing company forms expert team to expedite biopharmaceutical customer need for high throughput assay services. NYSE: CVD

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Covance today announced its Biomarker Expert Team, a panel of top scientists representing Covance's capabilities for providing technical and scientific expertise for customers in the selection, development, validation and testing of biomarker assays across the drug development continuum.

"Through our market research, we have identified a significant need that exists in drug development for high throughput biomarker development services," said Deborah Tanner, President, Covance Central Laboratory Services. "Our Biomarker Expert team offers decades of experience in biomarker testing and validation, which combined with our high throughput capabilities will significantly increase the effectiveness and efficiency of our clients' drug development programs." Covance's Biomarker Expert Team will enhance communication on all biomarker related services while supporting the ongoing testing and validation of biomarker assays, including work on custom biomarker assays.

As the world's largest provider of central laboratory services, Covance offers large-scale sample management and the highest throughput in the industry as the world's largest biomarker testing facility due to the quantity of biomarker tests completed. Covance offers nearly all biomarker testing needs directly or in collaboration with its qualified referral laboratories. In addition to providing globally the highest throughput of GLP and non-GLP biomarker services from its central laboratory, bioanalytical and toxicology laboratories, Covance offers bioimaging capabilities and cardiac-related biomarkers for both animals and humans.

Clinically useful biomarkers are required to inform therapeutic decision making regarding candidate drugs and related indications in order to help bring new medicines to the right patients faster. Effective use of biomarkers leads to faster decisions to continue or suspend a drug's development, saving pharmaceutical manufacturers money by reducing late stage failures while improving predictability of success.

Pharmaceutical companies are using biomarkers for nearly every new drug candidate, and it is predicted that within the next ten years biomarkers will be a standard aspect of drug development for any novel candidate. The FDA has made biomarkers central to the Critical Path initiative it launched in March 2004 with the aim of modernizing and streamlining medical product development.

About Covance
Covance (covance.com), with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.3 billion, global operations in more than 20 countries, and more than 8,100 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website.

Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to an qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission.

Covance and the Covance are registered service marks of Covance in the United States and other countries.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Covance, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Covance Announces Biomarker Expert Team Dedicated to Development Validation Testing of Biomarkers

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Ron Lee - Covance.com 
1-800-268-2623 netpr[.]covance.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Covance, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Covance, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  NAKIVO, Inc.

Visit  Intrinsic Executive Search Ltd

Visit  JobsWare.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today